Lower chemo dose shows promise in melanoma cell therapy trial
NCT ID NCT06151847
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study tested a treatment for advanced melanoma that cannot be removed by surgery or has spread. It used a lower dose of chemotherapy followed by infusion of the patient's own immune cells (lifileucel) grown from their tumor. The goal was to see if this approach is safe and how the immune system responds. 11 people took part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.